It’s always a good idea to keep track of insider buying.
After all, it’s the insiders that know their company the best. And if they’re putting their money where their mouths are, there’s usually a reason for it.
Just don’t use insider buying as a sole reason for buying. Do your own due diligence, too.
That being said, here’s what insiders are buying.
Oracle (SYM:ORCL)
With Oracle starting to pivot higher, director Charles “Wick” Moorman paid $950,000 on Feb. 12 for 5,500 Oracle shares, an average price of $172.35 each. The last time he bought shares was in January 2022 when he paid $1.3 million for 15,000 shares.
Helping, analysts at Jefferies reiterated a buy rating on ORCL with a price target of $220. The firm believes the DeepSeek pullback was overdone, adding that DeepSeek is just “part of an ongoing evolution, not revolution” of artificial intelligence.
Wynn Resorts (SYM:WYNN)
With Wynn Resorts recovering lost ground, director Paul Albert Liu just bought 1,600 shares on February 19 for about $147,904. Director Philip Satre bought 22,220 shares of February 18 for just over $2 million. Fueling upside, the company’s EPS of $2.42 just beat by $1.15. Revenue of $1.84 billion beat by $70 million. And the company declared a 25-cent dividend, which is payable on March 5 to shareholders of record as of February 24.
MBX Biosciences (SYM:MBX)
Director Carl Gordon just bought 190,672 shares of MBX for just over $2 million. This was executed at prices between $9.85 and $10.84 between February 14 and 18, 2025.
Reportedly, the company announced positive Phase 1 results for MBX 1416, its investigational GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) treatment. The trial, involving 69 healthy volunteers, demonstrated that MBX 1416 was generally well-tolerated with a favorable safety profile.
